PharmaTimes: News RSS
ABPI suspends Astellas UK for a further year
Astellas UK’s membership of the Association of the British Pharmaceutical Industry has been suspended for a further 12 months because of a number of “serious breaches” of the Code of Practice.
NICE turnaround for AstraZeneca’s COPD drug Daxas
AstraZeneca’s Daxas is now likely to be routinely available on the NHS to patients with chronic obstructive pulmonary disease (COPD), after new evidence helped persuade cost regulators that the drug is value for money in this setting.
US nod for CSL Behring’s HAE prevention therapy
US regulators have approved CSL Behring’s Haegarda, the first C1 esterase inhibitor for subcutaneous administration to prevent hereditary angioedema (HAE) attacks in adolescent and adults
Green light for Novartis’ lung cancer combination therapy
Novartis’ combination therapy Tafinlar + Mekinist has won approval from the US Food and Drug Administration to treat patients with metastatic non-small cell lung cancer (NSCLC) carrying the BRAF V600E mutation.
NHS England re-opens innovation accelerator scheme
NHS England is again issuing a call for the world’s “best healthcare innovations” to improve frontline patient care in a further round of the NHS Innovation Accelerator programme.
Is your commercial team the best in the industry£
If the answer is yes, take the first step toward getting your hands on the coveted Pharma by entering your Commercial Cross Functional Team into Marketer of the Year, today!
Communications Teams - Seize the opportunity to shine
Seize the opportunity to show off your skills and abilities as an agency in the Communications Team of the Year competition.
Novartis drug cuts cardiovascular risk in heart attack survivors
An experimental antibody being developed by Novartis has cut cardiovascular risk in patients who have survived a heart attack in a late-stage study.
DMD patients in the UK win early access to Santhera’s Raxone
Santhera Pharmaceuticals’ Raxone has become the first drug for Duchenne Muscular Dystrophy (DMD) to join the UK’s Early Access to Medicines Scheme (EAMS).
Shire secures US nod for once-daily ADHD drug
Shire has finally bagged approval in the US for its long-acting attention deficit hyperactivity disorder drug (ADHD) Mydayis.
EU regulators review Novartis’ migraine drug
An experimental therapy being developed by Amgen and Novartis to prevent migraine has been accepted for review in the European Union.
Charity sets eight new ‘grand challenges’ to combat cancer
Earlier detection of cancer through interrogation of medical and non-medical data sets using machine and deep-learning is one of eight new key quests set by Cancer Research UK in the second phase of its Grand Challenge Fund.
Parexel to go private in $5bn deal
Parexel International is being snapped up by private equity group Pamplona Capital Management in a deal valued at around $5 billion, including debt, marking further consolidation of the contract research sector.
Novartis’ eye drug on par with Eylea but with fewer injections
Novartis’ eye drug brolucizumab has been proven in trials to be non-inferior to Regeneron/Bayer’s Elyea in treating vision loss in patients with neovascular age-related macular degeneration (nAMD), but with fewer injections than its rival.
Global drug sales forecast to take a downturn
For the first time in 10 years global sales of pharmaceuticals are forecast by Evaluate to take a downturn because of growing pricing pressures.
Feed Fetched by RSS Dog.